StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Argus Reiterates Buy Rating on Moderna (MRNA), 'Discounted price offers buying opportunity'
June 9, 2022 11:09 AM
Argus analyst John Eade reiterated a Buy rating and $180.00 price target on Moderna (NASDAQ: MRNA).The analyst comments "We are ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Hot Comments
Next Articles
Moderna (MRNA) June weekly IV elevated as shares sell off 6.4%
June 9, 2022 10:58 AM
Moderna (MRNA) Trades at Low, Down 6.3%
June 9, 2022 10:54 AM
Moderna (MRNA) Climbs 4%
June 8, 2022 9:38 AM
Moderna says Omicron-targeted COVID shot shows better response
June 8, 2022 7:22 AM
Moderna (MRNA) Booster Candidate Demonstrates Superior Antibody Response Against Omicron
June 8, 2022 7:07 AM
Moderna Announces Omicron-Containing Bivalent Booster Candidate mRNA-1273.214 Demonstrates Superior Antibody Response Against Omicron
June 8, 2022 7:02 AM
Novavax's COVID-19 Vaccine Wins FDA AdCom Blessing, Removing 'Major Overhang'
June 7, 2022 5:37 PM
Moderna (MRNA) Doses First Participants in Phase 3 Study of Seasonal Influenza Vaccine Candidate (mRNA-1010)
June 7, 2022 7:03 AM
Moderna Announces First Participants Dosed in Phase 3 Study of Seasonal Influenza Vaccine Candidate (mRNA-1010)
June 7, 2022 7:02 AM
